Q5114 Injection ogivri 10 milligrams
Also known as: Ogivri injection, trastuzumab-drrx
Injection of Ogivri, trastuzumab-drrx biosimilar per 10 milligrams, a HER2-targeted monoclonal antibody.
In Plain Language
breast cancer immunotherapy; targeted biologic
Clinical Context
Used for HER2-positive breast and gastric carcinomas as adjuvant and metastatic therapy.
RVU Information
CPT Q5114 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Q-codes are temporary HCPCS codes used when no permanent code exists. Coverage and reimbursement vary by payer and region. Document the clinical indication and medical necessity. These codes may be replaced by permanent codes in future HCPCS updates.
Specialties
Frequently Asked Questions
What is CPT code Q5114?
CPT Q5114 (Injection ogivri 10 milligrams) is a Q Codes code. Injection of Ogivri, trastuzumab-drrx biosimilar per 10 milligrams, a HER2-targeted monoclonal antibody.
Is Q5114 covered by insurance?
Q5114 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Used for HER2-positive breast and gastric carcinomas as adjuvant and metastatic therapy.
When is CPT Q5114 used?
Used for HER2-positive breast and gastric carcinomas as adjuvant and metastatic therapy.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.